Efficacy and safety of palbociclib plus endocrine therapy for patients with HR⁺/HER2^- advanced breast cancer in real-world clinical practice.

ABSTRACT:

Background

Palbociclib is the first cyclin dependent kinase 4/6 (CDK4/6) inhibitor approved in China to be combined with endocrine therapy (ET) for patients with hormone receptor-positive (HR⁺)/human epidermal growth factor receptor 2-negative (HER2^-) metastatic breast cancer. However, palbociclib has only been used in China for a short amount of time, and there is limited data on its real-world applications. This study observed the efficacy and safety of palbociclib plus ET in a real-world setting in southwest China and we hope to provide some references for the treatment of patients with breast cancer in China.

Methods

This was an observational study of patients with HR⁺/HER2^- advanced breast cancer (ABC) who received palbociclib

SUBMITTER: Zhong B 

PROVIDER: S-EPMC9011297 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature